These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1768677)

  • 21. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
    J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy with IL2 by constant infusion and weekly doxorubicin.
    Paciucci PA; Bekesi JG; Ryder JS; Odchimar R; Chahinian PA; Holland JF
    Am J Clin Oncol; 1991 Aug; 14(4):341-8. PubMed ID: 1830717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.
    Yoneda K; Yamamoto T; Ueta E; Osaki T
    J Clin Immunol; 1992 Jul; 12(4):289-99. PubMed ID: 1512302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A; Savona S; Gafney E; Penichet KO; Lin BY; Levitt D; Ahmed T; Arlin ZA; Baskind P; Needleman D
    J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous infusion of recombinant interleukin-2 and lymphokine-activated killer cells in refractory malignancies.
    Christiansen NP; Kennedy BJ; Ochoa AC; Skubitz KM; Bach FH
    Med Pediatr Oncol; 1989; 17(6):455-8. PubMed ID: 2586359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
    Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunotherapy of tumors using interleukin-2 and lymphokine-activated killer cells].
    Jost LM; Gmür J; Oelz O; Sauter C; Stahel RA
    Schweiz Med Wochenschr; 1988 Feb; 119(5):137-43. PubMed ID: 3266369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ; Silver HK; Kong S
    Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
    Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
    J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
    Creekmore SP; Harris JE; Ellis TM; Braun DP; Cohen II; Bhoopalam N; Jassak PF; Cahill MA; Canzoneri CL; Fisher RI
    J Clin Oncol; 1989 Feb; 7(2):276-84. PubMed ID: 2783732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
    Choi BS; Sondel PM; Hank JA; Schalch H; Gan J; King DM; Kendra K; Mahvi D; Lee LY; Kim K; Albertini MR
    Cancer Immunol Immunother; 2006 Jul; 55(7):761-74. PubMed ID: 16187086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients.
    Sosman JA; Kefer C; Fisher RI; Jacobs CD; Pumfery P; Ellis TM
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):171-80. PubMed ID: 7613643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects.
    De Laurenzi A; Iudicone P; Zoli V; De Rosa L; Guglielmetti M; Pescarollo A; Papetti C; Pacilli L; Lapponi P; Petti N
    J Hematother; 1995 Apr; 4(2):113-20. PubMed ID: 7633841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.
    Urba WJ; Steis RG; Longo DL; Kopp WC; Maluish AE; Marcon L; Nelson DL; Stevenson HC; Clark JW
    Cancer Res; 1990 Jan; 50(1):185-92. PubMed ID: 2293554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity.
    Park KG; Heys SD; Murray JB; Hayes PD; Ashby JA; Franks CR; Eremin O
    Cancer Immunol Immunother; 1992; 35(1):53-8. PubMed ID: 1611623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells.
    Foon KA; Walther PJ; Bernstein ZP; Vaickus L; Rahman R; Watanabe H; Sweeney J; Park J; Vesper D; Russell D
    J Immunother (1991); 1992 Apr; 11(3):184-90. PubMed ID: 1515423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
    Phillips JH; Gemlo BT; Myers WW; Rayner AA; Lanier LL
    J Clin Oncol; 1987 Dec; 5(12):1933-41. PubMed ID: 3500280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Eberlein TJ; Rodrick ML; Massaro AF; Jung SE; Mannick JA; Schoof DD
    Cancer Immunol Immunother; 1989; 30(3):145-50. PubMed ID: 2598183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.